SpencerJA, TomlinsonAJ, WestonMJ, Early report: comparison of breath-hold MR excretory urography, Doppler ultrasound and isotope renography in evaluation of symptomatic hydronephrosis in pregnancy. Clin Radiol2000;55:446–53
9.
BirchardKR, BrownMA, HyslopWB, MRI of acute pelvic and abdominal pain in pregnant patients. Am J Roentgenol2005;184:452–8
10.
De SantisM, StrafaceG, CavaliereAF, Gadolinium periconceptual exposure: pregnancy and neonatal outcome. Acta Obstet Gynecol2007;86:99–101
11.
Kubik-HuchRA, Gottstein-AalameNM, FrenzelT, Gadopentetate dimeglumine excretion into human breast milk during lactation. Radiology2000;216:555–8
12.
Marti-BonmatiL, VegaT, BenitoC, Safety and efficacy of Omniscan (gadodiamide injection) at 0.1 mmol/kg for MRI in infants younger than 6 months of age: phase 111 open multicenter study. Invest Radiol2000;35:141–7
13.
Tsai-GoodmanB, GevaT, OdegardKC, Clinical role, accuracy and technical aspects of cardiovascular magnetic resonance imaging in infants. Am J Cardiol2004;94:69–74
14.
WeinmannHJ, BraschRC, PressWR, Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol1984;142:619–24
15.
TweedleMF, WedekingP, KumarK. Biodistribution of radiolabelled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol1995;30:372–80
16.
SieberMA, LengsfeldP, FrenzelT, Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol2008;18:2164–73
17.
WhiteGW, GibbyWA, TweedleMF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd (HP-DO3A) (Prohance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol2006;41:272–8
18.
AbrahamJL, ThakralC, SkovL, Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol2008;158:271–80
19.
K-DOQI Clinical Practice Guidelines Part 4.Definitions and classification of stages of chronic kidney disease. Am J Kidney Dis2002;39 (Suppl. 1):S46–75
20.
21.
22.
ThomsenHS, MorcosSK, AlmenT, Nephrogenic systemic fibrosis and gadolinium based contrast media: updated ESUR Contrast Medium Safety Committee Guidelines. Eur Radiol2013;23:307–18
